A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants

NCT01762839 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Single-Dose IV Oritavancin Diphosphate
DRUG: Placebo
DRUG: Moxifloxacin

Sponsor

Melinta Therapeutics, Inc.